Tumor News and Research

RSS

Aptose joins Beat AML research collaboration

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, the Knight Cancer Institute at Oregon Health & Science University and The Leukemia & Lymphoma Society today announced that Aptose has joined the Beat AML collaboration.

29 Sep 2014

Myriad Genetics' Tumor BRACAnalysis CDx identifies 44% more candidates for PARP therapy

Myriad Genetics, Inc. today announced that its Tumor BRACAnalysis CDx- companion diagnostic test significantly improved the detection of cancer-causing BRCA1/2 mutations by 44 percent in women with ovarian cancer. Data from this new study were presented at the 2014 European Society for Medical Oncology annual meeting in Madrid, Spain.

29 Sep 2014

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung cancer and ovarian cancer.

29 Sep 2014

Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

The recent launch of two clinical trials offer innovative study designs for patients with lung cancer. These clinical trials are the direct result of a National Cancer Institute sponsored workshop chaired by Drs. Fred R. Hirsch, Shakun Malik and Claudio Dansky- Ullman, that brought together the NCI Thoracic Malignancies Steering Committee, the US Food and Drug Administration, academicians, clinicians as well as industry and government stakeholders to discuss issues and challenges related to clinical trial design and biomarkers for lung cancer targeted-therapies.

29 Sep 2014

Crizotinib drug effectively halts growth of ROS1-positive lung tumors

Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene. In an article receiving Online First publication in the New England Journal of Medicine to coincide with a presentation at the European Society for Medical Oncology meeting, an international research team reports that crizotinib treatment led to significant tumor shrinkage in 36 of 50 study participants and suppressed tumor growth in another 9.

29 Sep 2014

Scientists discover sign of early development of pancreatic cancer

Scientists at Dana-Farber Cancer Institute, the Massachusetts Institute of Technology, and other institutions have discovered a sign of the early development of pancreatic cancer - an upsurge in certain amino acids that occurs before the disease is diagnosed and symptoms appear.

29 Sep 2014

EMD Serono declares winners of first Grant for Oncology Innovation

EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, today announced the winners of the first Grant for Oncology Innovation (GOI), who will receive grants totaling $1.3 million.

27 Sep 2014

Researchers develop new strategy for reducing serious side effects of modern anticancer drugs

An interdisciplinary team of researchers from the University of Vienna (Institute of Inorganic Chemistry) and the Medical University of Vienna (Institute for Cancer Research) has successfully developed a new strategy for reducing the often serious side effects of an important class of modern anticancer drugs (tyrosine kinase inhibitors).

26 Sep 2014

Scientists discover new clues about drug used in treating blood cancer

Keck Medicine of USC scientists have discovered new clues about a drug instrumental in treating a certain blood cancer that may provide important targets for researchers searching for cures.

26 Sep 2014

Lya Segall Ovarian Cancer Institute at Mercy opens in Maryland

Mercy Medical Center has announced the opening of The Lya Segall Ovarian Cancer Institute at Mercy, the first center in Maryland specifically designed and dedicated solely for the diagnosis and treatment of ovarian cancer.

26 Sep 2014

Study findings have potential to advance treatments for small cell lung cell cancer

Two recently published studies by a research team at University Hospitals Case Medical Center Seidman Cancer Center have the potential to advance treatments for small cell lung cell cancer (SCLC). This aggressive form of lung cancer has seen no treatment advances in 30 years and "is a disease in urgent need of new drug therapies," write the study's authors.

26 Sep 2014

Colorado cancer researchers launch feasibility study to build nation's first carbon-ion radiotherapy facility

Colorado cancer researchers and medical doctors on Wednesday announced they are launching a $200,000 feasibility study as a key step to building the nation's first carbon-ion radiotherapy research and treatment facility in Aurora, where they and colleagues hope to investigate and provide to patients leading-edge radiation therapy that is effective against the deadliest cancers and now is available only in Europe and Japan.

25 Sep 2014

NCCN ORP awards four research grants to advance development of nintedanib

The National Comprehensive Cancer Network Oncology Research Program has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal cancers.

25 Sep 2014

Ohio State researchers develop novel anticancer peptide vaccines and inhibitors

Researchers have developed two new anticancer peptide vaccines and two peptide inhibitors as part of a larger peptide immunotherapy effort at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

25 Sep 2014

Researchers reveal why RB1 gene mutations primarily cause retinoblastomas in children

Retinoblastoma is a childhood retinal tumor usually affecting children one to two years of age. Although rare, it is the most common malignant tumor of the eye in children.

25 Sep 2014

AIT, BioVendor and SCIENION partner to develop in-vitro diagnostic test for colon cancer

The AIT Austrian Institute of Technology, BioVendor and SCIENION today announced that the three companies will partner on the development of an in-vitro diagnostic test for colon cancer. The innovative test kit shall identify cancer at an early stage based on tumor autoantibody biomarkers.

24 Sep 2014

ImmunoCellular signs licensing agreement with Caltech to develop antigen-specific T-cell technology

ImmunoCellular Therapeutics, Ltd. announced today that it has established a licensing agreement with the California Institute of Technology for exclusive rights to novel technology for the development of certain antigen specific T-cell immunotherapies for the treatment of cancer.

24 Sep 2014

ANN expands commitment to BCRF through annual Breast Cancer Awareness campaign

ANN INC., the parent Company of Ann Taylor and LOFT, today announces its expanded commitment to The Breast Cancer Research Foundation through its annual Breast Cancer Awareness campaign and latest in-store and online promotions.

24 Sep 2014

Researchers explore gene expression in normal vestibular nerves, vestibular schwannomas

Researchers from the University of Toronto, directed by Drs. Gelareh Zadeh and Boris Krischek, investigated gene expression in normal vestibular nerves and vestibular schwannomas (VSs).

24 Sep 2014

XenOPAT aims to advance development of new drugs against cancer, personalized cancer treatments

On September 8th, the company XenOPAT SL, a spin-off of the Institute of Biomedical Research and the Catalan Institute of Oncology was established with the aim of bringing the company the latest scientific developments to the service combating cancer with two main branches: the development of new drugs and advance the implementation of personalized cancer treatments.

24 Sep 2014

Tumor News and Research

Aptose joins Beat AML research collaboration

Myriad Genetics' Tumor BRACAnalysis CDx identifies 44% more candidates for PARP therapy

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

Crizotinib drug effectively halts growth of ROS1-positive lung tumors

Scientists discover sign of early development of pancreatic cancer

EMD Serono declares winners of first Grant for Oncology Innovation

Researchers develop new strategy for reducing serious side effects of modern anticancer drugs

Scientists discover new clues about drug used in treating blood cancer

Lya Segall Ovarian Cancer Institute at Mercy opens in Maryland

Study findings have potential to advance treatments for small cell lung cell cancer

Colorado cancer researchers launch feasibility study to build nation's first carbon-ion radiotherapy facility

NCCN ORP awards four research grants to advance development of nintedanib

Ohio State researchers develop novel anticancer peptide vaccines and inhibitors

Researchers reveal why RB1 gene mutations primarily cause retinoblastomas in children

AIT, BioVendor and SCIENION partner to develop in-vitro diagnostic test for colon cancer

ImmunoCellular signs licensing agreement with Caltech to develop antigen-specific T-cell technology

ANN expands commitment to BCRF through annual Breast Cancer Awareness campaign

Researchers explore gene expression in normal vestibular nerves, vestibular schwannomas

XenOPAT aims to advance development of new drugs against cancer, personalized cancer treatments

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News